Adesis, Inc., a leading contract research organization (CRO) supporting the pharmaceutical and biopharmaceutical industries and a wholly-owned subsidiary of Universal Display Corporation has appointed Helen Stimson as its Chief Operating Officer. Stimson brings to the position a wealth of knowledge in the biotech and life science sectors, advising on business development and transformation, strategic planning and marketing on a state, national and global level. She will join Adesis on June 1, 2020 and lead the operational, sales and marketing aspects of the CRO business.
“It is with great pleasure to announce that Helen Stimson is joining Adesis,” said Andrew Cottone, Ph.D., President of Adesis, Inc. “Adesis has built a strong reputation as a strategic scientific partner with more than 20 years of chemistry and technical prowess. As a seasoned executive with a robust business and science background, I believe Helen will be an excellent addition to our team to help spearhead Adesis to its next phase of growth.”
Prior to joining Adesis, Stimson was CEO of Delaware Bioscience Association. She also held an Executive leadership post at Agilent Technologies, a laboratory instrument maker, running its global consumables division.
“I look forward to contributing to the amazing growth and enabling core competencies of Adesis,” said Stimson. “Adesis is well-known and respected as a leader in chemical research for transforming ideas on a whiteboard into developmental and commercial compounds. I have admired Adesis’ talented people and brilliant work for some time, and am excited to help build upon the company’s solid foundation and positive momentum alongside its employees, partners and customers.”
